EMBRYONIC LETHALITY
DUE TO HEMORRHAGE AROUND E11.5

A



Fli-1(-I-) Fli-1(+I-)

B



C

D

A. *Fli-1* Heterozygote and homozygote at day 11.5 of development. Homozygous *Fli-1*$^{-/-}$ embryos that were alive at E11.5 had significant intracranial hemorrhages.

B. *Fli-1* expression assessed by wholemount ß-galactosidase staining of a *Fli-1* heterozygote at E11.5. Intersomitic blood vessels (small arrow) and major cerebral blood vessels (large arrow). Magnification, 5x.

C. *Fli-1* expression assessed by ß-galactosidase activity is present at the sites of intracranial hemmorrage. Saggital section of E11.5 *Fli-1*$^{-/-}$ homozygote. Intracranial hemorrhages (arrows) are present in the forebrain. Magnification, 10x. Asterisk shows arrow indicating area shown at higher magnification.

D. Higher magnification of E11.5 *Fli-1*$^{-/-}$ sagital section. Magnification, 50x. Endothelial cells of the forebrain meninges expressing the *lacZ* reporter appear attenuated and discontinuous (arrow).

Research/Image:
Reprinted from Immunity, Volume 13, Number 2, by Adam Hart, Fabrice Melet, Paul Grossfeld, Kenneth Chien, Christopher Jones, Alan Tunnacliffe, Remi Favier and Alan Bernstein in Fli-1 is Required for Murine Vascular and Megakaryocytic Development and Is Hemizygously Deleted in Patients with Thrombocytopenia, pages 167-177, 2000, with permission from Elsevier Science.

sunday	monday	tuesday	wednesday	thursday	friday	saturday
						1
2	Labour Day 3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	Rosh Hashanah 21	22
23 30	24	25	Yom Kippur 26	27	28	29

SEPTEMBER
2001

Dr. ALAN BERNSTEIN

President of the Canadian Institutes of Health Research (CIHR)

Mandate: CHIR is Canada's premier funding federal agency for health research. Its objective is to excel in the creation of new knowledge and its translation into improved and effective health services for Canadians.

Dr. Alan Bernstein is known internationally both as a researcher and as a scientific leader. His pioneering research in the area of cancer, hematopoiesis and gene therapy remain landmarks in their field. Dr. Bernstein was the first Anne Tanenbaum Chair in Molecular and Developmental Biology at the Samuel Lunenfeld Research Institute at the Mt. Sinai Hospital in Toronto from 1990-2000. As a scientific leader, Dr. Bernstein was highly successful in building and nurturing the Lunenfeld Institute into one of Canada's premier health research institutes.